A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is sure to face legal challenges, experts say.

The company established a new protocol for the study and will advance its drug response predictor as a companion diagnostic.

The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.

The firm will take a different reimbursement strategy for the test than its prior owner Biocept, which stopped selling it after filing for bankruptcy in 2023.

The therapy, which delivers COL7A1 transgenes by eyedrop, was used previously to treat a patient under a compassionate use protocol.